Celator Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock

On Oct 17, 2014

Ewing-based Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, announces that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock. Roth Capital Partners and National Securities Corporation are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Related Articles: